Clinical trials: Early Lung Cancer
Non-small Cell Lung Carcinoma
Evaluation of FLT-PET and DWI-MRI in Patients With NSCLC Treated With a Platinum-based Doublet as Preoperative Chemo
The purpose of the study is to qualify, independently, tumor cell proliferation by 3'-Deoxy-3'-[18F]Fluorothymidine (FLT) -Positron Emission Tomography , and cell death by Diffusion Weighted Imaging (DWI) -Magnetic Resonance…
- Trial name
- EVIDENCE (NCT02273271)
- Testing
- 18F-FLT-PET/CT and DWI-MRI
- Where
- 2 sites in Italy, United Kingdom
- Volunteers
- 31 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Non-small Cell Lung Cancer
Neoadjuvant Itraconazole in Non-small Cell Lung Cancer
The purpose of this study is to determine the pharmacodynamics effects of itraconazole in early-stage non-small cell lung cancer.
- Trial name
- NCT02357836
- Testing
- Itraconazole
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Texas Southwestern Medical Center
Non-Small Cell Lung Cancer
To Explore the Safety and Efficacy of Hypervision Proton Surgery for Early-stage Non-small Cell Lung Cancer
This study was a single-center, single-arm clinical study to evaluate the safety and efficacy of hypervision proton surgery with single large fractionated doses (34GyE and 39GyE) in the treatment of early peripheral NSCLC.
- Trial name
- HyPROS-LC (NCT07195084)
- Testing
- Hypervision proton surgery
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Anhui Provincial Cancer Hospital
Clinical Decision-Making, Early Detection of Cancer
Evaluation of the Cell Detachment Ratio on pH-responsive Chitosan as a Prognostic Factor in Lung Cancer
Biomaterial-based cell culture models have been gaining increasing attention as potential therapeutic strategies. The purpose of this project is to evaluate whether the cell detachment ratio on pH-responsive chitosan could be…
- Trial name
- NCT04218188
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- National Taiwan University Hospital
Lung Cancer, Nonsmall Cell
Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
This is a prospective, randomized, single-site, open-label Phase II trial of neoadjuvant pembrolizumab (3 cycles) followed by surgery, versus concomitant neoadjuvant pembrolizumab with platinum doublet chemotherapy (3 cycles)…
- Trial name
- NCT04638582
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- Canada
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Non-Small-Cell Lung Carcinoma
Molecular Imaging With Erlotinib and Bevacizumab
The patients will be treated with erlotinib and bevacizumab for a six-week period. Imaging procedures will be performed at baseline, after one week of therapy and after the six weeks of treatment.
- Trial name
- MIMEB (NCT01047059)
- Testing
- Erlotinib, Bevacizumab, Fluoro-D-glucose, Fluoro-L-thymidine
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- University of Cologne
Pulmonary Nodules, Early-Stage Lung Cancer
Application of Electromagnetic Navigation System in Pulmonary Nodule Localization
This study aims to design and conduct a multicenter, prospective, randomized controlled post-market clinical trial to validate the clinical efficacy of high-precision electromagnetic navigation technology.
- Trial name
- NCT07595120
- Testing
- Electromagnetic Navigation-Guided Percutaneous Localization of Pulmonary Nodules, CT-Guided Percutaneous Localization of Pulmonary Nodules
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Carcinoma, Non-Small-Cell Lung
Prognostic Value of PD-L1 in NSCLC
This is an observational retrospective study. The primary objective is to investigate the expression and potential prognostic role of Programmed Death Ligand 1 (PD-L1) in tumor samples from 350 patients with early stage…
- Trial name
- NCT03078959
- Testing
- immunohistochemistry
- Volunteers
- 350 people
- Sponsor
- Fondazione Ricerca Traslazionale
Malignant Pleural Mesothelioma
Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM
This is a multicenter, randomized, 1:1, non-comparative phase II trial. Patients with early stage MPM will be randomized between Arm A: immediate P/D followed by three cycles of chemotherapy (pemetrexed 500mg/m2 and cisplatin 75…
- Trial name
- NCT02436733
- Testing
- pleurectomy/decortication, Pemetrexed/Cisplatin
- Where
- 4 sites in Belgium, Netherlands
- Volunteers
- 64 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lung Cancer
Manchester Lung Health Study
The Manchester Lung Health Study (qUEST) will assess the uptake of a community-based lung cancer screening service and its impact across a deprived area of North and East Manchester, which has high rates of lung cancer.
- Trial name
- qUEST (NCT04409444)
- Testing
- Lung Cancer Screening, Biomarkers
- Where
- United Kingdom
- Volunteers
- 9,730 people
- Sponsor
- Manchester University NHS Foundation Trust
Malignant Pleural Mesothelioma
Response Evaluation in Malignant Pleural Mesothelioma
Recently, a few small trials have shown promising results on value of fluoro-2-deoxy-D-glucose and positron emission tomography imaging in response assessment in Malignant Pleural Mesothelioma.
- Trial name
- NCT00969098
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Istituto Clinico Humanitas
NSCLC, EGFR Gene Mutation
A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases
This study involves patients with EGFR-mutated NSCLC and asymptomatic brain metastases. This is an open-label, randomized study, comparing the continuation of Osimertinib treatment alone to Osimertinib treatment combined with…
- Conditions
- NSCLC, EGFR Gene Mutation, EGF-R Positive Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05033691
- Testing
- Stereotactic surgery
- Where
- Israel
- Volunteers
- 162 people
- Sponsor
- Hadassah Medical Organization
Lung Cancer
Effect on Patient Reported Outcomes of VATS and SABR (LILAC)
This study will monitor the effect on patients reported outcomes (PROMs) of VATS resection and SABR for NSCLC delivered at the Leeds Cancer Centre The investigator will support with this information the Shared Decision Making…
- Trial name
- LILAC (NCT02882750)
- Testing
- EORTC QLQ-C30 (version 3.0)., PS Q18, Decision Self-Efficacy Scale
- Volunteers
- 244 people
- Sponsor
- University of Leeds
Lung Cancer
Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung
2,000 individuals, aged 50-80 who have received a lung-RADS category 3 or 4 result on a LDCT screening study and who are scheduled for follow-up diagnostic imaging study, biopsy, clinical consultation or surgical appointment at…
- Trial name
- NCT05987189
- Testing
- Small RNA-based lung cancer assay
- Where
- 11 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Hummingbird Diagnostics
Lung Cancer
Efficacy and Safety of Multimode Thermal Therapy in the Treatment of Early Peripheral Lung Cancer
The purpose of the study is to evaluate the efficacy and safety of multimode thermal therapy for early peripheral lung cancer, and to explore the changes of systemic immune microenvironment after multimode thermal therapy.
- Trial name
- NCT06453889
- Testing
- Multimode thermal therapy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai Chest Hospital
Non Small Cell Lung Cancer, Circulating Tumor Cell
WHENII - Early Response Evaluation With FDG-PET/CT and Liquid Biopsy in Patients With NSCLC
Response evaluation with FDG-PET and free circulating DNA in patients with inoperable lung cancer of non small cell type during first treatment with chemotherapy or immunotherapy.
- Conditions
- Non Small Cell Lung Cancer, Circulating Tumor Cell, Circulating Tumor DNA
- Trial name
- WHENII (NCT03481101)
- Testing
- PET/CT
- Where
- 2 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Erlotinib, Lung Cancer
The Role of Positron Emission Tomography (PET) During Erlotinib Treatment for Non-small Cell Lung Cancer
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. Higher response rates were observed in a subset of patients with female gender, Asian ethnicity, no smoking history, mutations in EGFR…
- Trial name
- NCT01000428
- Where
- South Korea
- Volunteers
- 34 people
- Sponsor
- Asan Medical Center
Non-small Cell Lung Cancer Stage I
Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer
Stage 1 non-small cell lung cancer (NSCLC) carries up to 30% chance of relapse in 5 years. This a phase 2 study that aims to determine the pathological complete response of the combination of stereotactic ablative radiotherapy…
- Trial name
- NCT04271384
- Testing
- nivolumab
- Where
- Brazil
- Volunteers
- 25 people
- Sponsor
- Hospital Israelita Albert Einstein
Early-Stage Lung Cancer, NSCLC
A Study Developing a Non-invasive Urine-based Proteomic Model for Early Lung Cancer Detection.
Brief Summary: The goal of this observational study is to develop a non-invasive urine proteomic diagnostic model to improve early-stage lung cancer detection.
- Conditions
- Early-Stage Lung Cancer, NSCLC, Pulmonary Nodule
- Trial name
- UPD-LC (NCT06733311)
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Beijing Chao Yang Hospital
Carcinoma, Non-Small-Cell Lung
Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer
Lung cancer is still the leading cause of cancer related-deaths worldwide, with an overall all-stage 5-year survival of approximately 17%. The primary treatment of early stage (I-IIIA) NSCLC is curative surgery.
- Trial name
- IONESCO (NCT03030131)
- Testing
- Durvalumab
- Where
- 31 sites in France
- Volunteers
- 50 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique